Drug Trial Radar · NCT06399289
Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy
Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Jul 28, 2024
Primary completion
Jul 7, 2026
Study completion Jul 7, 2026
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- May 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Male only, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the pharmacokinetics (PK), efficacy, and safety of rIX-FP for the routine prophylaxis of bleeding episodes in male Chinese previously treated patients (PTPs) with hemophilia B (FIX activity of ≤ 2%). In addition to the scheduled rIX-FP prophylaxis regimen, subjects may also receive rIX-FP episodic (on-demand) treatment for breakthrough bleeding episodes and rIX-FP for the prophylaxis and treatment of bleeding in emergency surgical procedures.
Conditions
- Hemophilia B
Interventions
Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)Biological
Lyophilized powder for solution for intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incremental recovery (IR) (plasma FIX activity)Time frame: Before, and at 30 minutes after the end of, rIX-FP infusion on Day 1
- Maximum plasma concentration (Cmax)Time frame: Before, and up to 336 hours after the end of, rIX-FP infusion on Day 1
- Terminal elimination half-life (t1/2) of rIX-FPTime frame: Before, and up to 336 hours after the end of, rIX-FP infusion on Day 1
- Area under the concentration-time curve (AUC)Time frame: Before, and up to 336 hours after the end of, rIX-FP infusion on Day 1
- Clearance (Cl) of rIX-FPTime frame: Before, and up to 336 hours after the end of, rIX-FP infusion on Day 1
- Annualized spontaneous bleeding rate (AsBR)Time frame: Up to 18 months
- Number of subjects who develop an inhibitor to FIXTime frame: Up to 18 months after rIX-FP infusion
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Beijing Children's Hospital
Beijing, Beijing Municipality, China
Union Hospital Affiliated to Fujian Medical University
Fuzhou, Fujian, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
North China University Of Science And Technology Affiliated Hospital
Tangshan, Hebei, China
Jinan Central Hospital
Jinan, Shandong, China
Hospital of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.